Clinical Trials
16 trialsNCT00421317 2026-03-13
O-Mel-Inib
Centre Oscar Lambret
Phase 2 Terminated
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT04598009 2025-09-03
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Phase 2 Recruiting
NCT01738139 2024-03-21
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04546074 2023-10-03
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
Phase 1/2 Unknown
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT00027586 2018-10-31
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00074308 2018-06-20
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02812693 2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00470470 2014-12-23
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00402662 2013-12-18
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Yale University
Phase 2 Terminated
NCT00068783 2013-02-28
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025415 2013-02-07
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT01782508 2013-02-04
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00881049 2011-01-17
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
Peking University
Phase 2 Completed